natgillin/translations-raw huggingface dataset:
Adverse reactions are listed by MedDRA body system organ class and by frequency: Very common (_≥1/10); Common (≥1/100 to &lt; 1/10); and Uncommon (≥ 1/1,000 to &lt; 1/100).
Nuspojave su prikazane prema MedDRA klasifikaciji organskih sustava i učestalosti nuspojava: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); i manje često (≥1/1000 i &lt; 1/100).
Adverse reactions are listed in Table 5 by regimen, system organ class and frequency: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Nuspojave su u Tablici 5 popisane prema režimu, organskim sustavima i učestalosti: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100) rijetko (≥1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to
Nuspojave su navedene redoslijedom od ozbiljnijih prema manje ozbiljnima i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Nuspojave su prikazane u padajućem nizu prema ozbiljnosti i njihova učestalost je definirana na sljedeći način: vrlo često: (≥1/10); često: (≥1/100 do &lt; 1/10); manje često: (≥1/1000 do &lt; 1/100); rijetko: (≥1/10 000 do &lt; 1/1000) i vrlo rijetko: ( &lt; 1/10 000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000)
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova učestalost je definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći iduću konvenciju: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to
Nuspojave su navedene prema klasifikaciji organskih sustava primjenom sljedeće konvencije: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema klasifikaciji organskih sustava, koristeći iduću konvenciju: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked by system organ class and frequency ([very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000)]).
Nuspojave su navedene prema klasifikaciji organskih sustava i učestalosti ([vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000)]).
Adverse reactions are ranked by System organ class and then by frequency with the most frequent first, using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Nuspojave su poredane po klasifikaciji organskih sustava i zatim po učestalosti, pri čemu su najučestalije navedene prve, prema sljedećoj konvenciji: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1000 to &lt; 1/100), rare (≥1/10000 to &lt; 1/1000), very rare ( &lt; 1/10000).
Nuspojave su poredane prema učestalosti javljanja koristeći sljedeće pravilo: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100, &lt; 1/10), uncommon (≥1/1000, &lt; 1/100), rare (≥1/10000, &lt; 1/1000), very rare ( &lt; 1/10000).
Nuspojave su poredane prema učestalosti javljanja koristeći sljedeće pravilo: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Nuspojave su razvrstane prema sljedećim kriterijima učestalosti, pri čemu se prvo navode one najčešće: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common 1/10), common 1/100 to &lt; 1/10), uncommon 1/1,000 to &lt; 1/100), rare 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions considered to be related to clofarabine reported at frequencies ≥ 1/1,000 (i.e. in &gt; 1/115 patients) in clinical trials and post-marketing
Nuspojave za koje se smatra da su povezane s klofarabinom prijavljene s učestalošću od ≥ 1/1000 (tj. u &gt; 1/115 bolesnika) u kliničkim ispitivanjima i nakon stavljanja lijeka u promet
Adverse reactions from clinical trials and spontaneous reporting, occurring in &gt; 1% of patients, are listed in the table below by system organ class and frequency (very common:  1/10, common:
Nuspojave u kliničkim ispitivanjima i iz spontanih prijava bolesnika koje su se javljale kod &gt; 1%, bolesnika, navedene su u donjoj tablici prema klasifikaciji organskih sustava i učestalosti (vrlo često:  1/10, često:
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000).
Nuspojave su navedene prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Nuspojave su klasificirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥1/10); često (≥1/100 i
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Nuspojave su podijeljene prema učestalosti koja se definira kao: vrlo često (≥1/10); često (≥1/100 i
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000)
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1 000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000)
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000),
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasficirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1 000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasficirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasificirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasificirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1 000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasificirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema nazivima učestalosti uz uporabu sljedeće konvencije: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000; vrlo rijetko ( &lt; 1/10 000); nije poznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000; vrlo rijetko ( &lt; 1/10 000); nije poznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000; vrlo rijetko ( &lt; 1/10 000); nije poznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1 000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
Adverse reactions observed in 20 placebo-controlled studies and post-marketing experience with bosentan are ranked according to frequency using the following convention: very common ( 1/10); common (1/100 to &lt; 1/10); uncommon ( 1/1,000 to &lt; 1/100); rare ( 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Nuspojave uočene u 20 placebom kontroliranih studija s bosentanom i iskustvima nakon stavljanja lijeka na tržište poredane su prema učestalosti koristeći sljedeću konvenciju: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions occurring in &gt; 10% of cycles in either treatment group in Phase 1-4 study patients with lymphomatous meningitis receiving DepoCyte 50 mg (n = 151 cycles) or cytarabine (n = 99 cycles)
Nuspojave koje se pojavljuju u &gt; 10% ciklusa liječenja, u fazama 1-4 kliničkog ispitivanja, u pacijenata s limfomatoznim meningitisom koji su primali ili DepoCyte 50 mg (n = 151 ciklus) ili citarabin (n = 99 ciklusa)
Adverse reactions possibly reflecting neurotoxicity are listed in Table 2 by MedDRA body system organ class and by frequency: Very common (_≥1/10); Common (≥1/100 to &lt; 1/10); and Uncommon (≥ 1/1,000 to &lt; 1/100).
Nuspojave koje moguće ukazuju na neurotoksičnost prikazane su u tablici 2 prema MedDRA klasifikaciji organskih sustava i učestalosti nuspojava: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); i manje često (≥1/1000 i &lt; 1/100).
Adverse reactions reported at a very common (≥1/10), common (≥1/100 to &lt; 1/10) or uncommon (≥1/1,000 to &lt; 1/100) frequency with eculizumab are listed by system organ class and preferred term.
Nuspojave zabilježene uz ekulizumab kao vrlo česte (≥1/10), česte (≥1/100 i &lt; 1/10) ili manje česte (≥1/1000 i &lt; 1/100) navedene su prema klasifikaciji organskih sustava i preporučenim izrazima.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency.
Nuspojave zabilježene tijekom kliničkih studija (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency.
Nuspojave zabilježene tijekom kliničkih ispitivanja (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
Adverse reactions reported in excess ( &gt; 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Nuspojave koje su bile zabilježene češće ( &gt; 0,5%) nego uz placebo ili kao izolirani slučaj u bolesnika koji su primali pioglitazon u dvostruko slijepim ispitivanjima navedene su niže prema MedDRA pojmovima, klasifikaciji organskih sustava i apsolutnoj učestalosti.
Adverse reactions reported in excess ( &gt; 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Nuspojave koje su bile zabilježene češće (˃ 0,5%) nego uz placebo ili kao izolirani slučaj u bolesnika koji su primali pioglitazon u dvostruko slijepim ispitivanjima navedene su niže prema MedDRA pojmovima, klasifikaciji organskih sustava i apsolutnoj učestalosti.